VYNE Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

De winst van VYNE Therapeutics zal naar verwachting dalen met 18.2% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 70.6% per jaar. De winst per aandeel zal naar verwachting afnemen met 11.4% per jaar.

Belangrijke informatie

-18.2%

Groei van de winst

-11.4%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	23.8%
Inkomstengroei	70.6%
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	18 Nov 2024

Recente toekomstige groei-updates

Recent updates

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

Aug 12

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

Jul 02

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Mar 19

VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Jan 13

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Dec 03

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Aug 13

VYNE Therapeutics: Terrible Depreciation Of Shareholder Value

Jun 30

Despite Lacking Profits VYNE Therapeutics (NASDAQ:VYNE) Seems To Be On Top Of Its Debt

Jun 07

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

Feb 17

Breakeven On The Horizon For VYNE Therapeutics Inc. (NASDAQ:VYNE)

Feb 10

Winst- en omzetgroeiprognoses

NasdaqCM:VYNE - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	0	-61	N/A	-57	2
12/31/2025	0	-53	N/A	-49	2
12/31/2024	1	-40	N/A	-36	2
9/30/2024	0	-34	-30	-30	N/A
6/30/2024	0	-28	-27	-27	N/A
3/31/2024	0	-29	-28	-28	N/A
12/31/2023	0	-28	-25	-25	N/A
9/30/2023	0	-29	-25	-25	N/A
6/30/2023	0	-33	-27	-27	N/A
3/31/2023	0	-31	-26	-26	N/A
12/31/2022	0	-34	-29	-29	N/A
9/30/2022	1	-35	-34	-34	N/A
6/30/2022	1	-40	-45	-45	N/A
3/31/2022	1	-42	-53	-53	N/A
12/31/2021	1	-44	-56	-56	N/A
9/30/2021	5	-59	-72	-72	N/A
6/30/2021	8	-69	-78	-78	N/A
3/31/2021	19	-226	-97	-97	N/A
12/31/2020	21	-256	-137	-137	N/A
9/30/2020	17	-270	-134	-134	N/A
6/30/2020	14	-269	-133	-132	N/A
3/31/2020	2	-120	-110	-109	N/A
12/31/2019	0	-95	-74	-73	N/A
9/30/2019	1	-71	-63	-62	N/A
6/30/2019	2	-64	-62	-62	N/A
3/31/2019	3	-63	-63	-62	N/A
12/31/2018	4	-74	-69	-69	N/A
9/30/2018	4	-77	-71	-70	N/A
6/30/2018	4	-80	N/A	-69	N/A
3/31/2018	4	-77	N/A	-64	N/A
12/31/2017	4	-66	N/A	-53	N/A
9/30/2017	4	-59	N/A	-53	N/A
6/30/2017	6	-47	N/A	-36	N/A
3/31/2017	6	-39	N/A	-32	N/A
12/31/2016	6	-29	N/A	-27	N/A
9/30/2016	4	-24	N/A	-18	N/A
6/30/2016	2	-21	N/A	-19	N/A
3/31/2016	1	-18	N/A	-18	N/A
12/31/2015	1	-17	N/A	-12	N/A
9/30/2015	4	-11	N/A	-10	N/A
6/30/2015	4	-16	N/A	-7	N/A
3/31/2015	4	-15	N/A	-4	N/A
12/31/2014	5	-11	N/A	-1	N/A
9/30/2014	3	-12	N/A	1	N/A
6/30/2014	3	-4	N/A	1	N/A
3/31/2014	3	-2	N/A	2	N/A
12/31/2013	1	-2	N/A	0	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat VYNE de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat VYNE de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat VYNE de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van VYNE ( 70.6% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van VYNE ( 70.6% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van VYNE naar verwachting over 3 jaar hoog zal zijn

VYNE Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 13%

Consensus revenue estimates increase by 50%, EPS downgraded

Consensus EPS estimates upgraded to US$0.81 loss

Consensus EPS estimates upgraded to US$4.82 loss, revenue downgraded

Price target increased by 21% to US$16.50

Consensus revenue estimates increase by 60%, EPS downgraded

Recent updates

Consensus EPS estimates fall by 13%

VYNE Therapeutics Inc., Annual General Meeting, Dec 12, 2024

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

VYNE Therapeutics Announces Positive Phase 1A Sad Data for Vyn202, A Novel Bd2-Selective Bet Inhibitor

Consensus revenue estimates increase by 50%, EPS downgraded

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Inc. Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

Vyne Therapeutics Announces Dosing of First Participants in Phase 1A Trial of Novel Bd2-Selective Bet Inhibitor Vyn202

VYNE Therapeutics Inc. Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201

Consensus EPS estimates upgraded to US$0.81 loss

First quarter 2024 earnings released: US$0.15 loss per share (vs US$1.72 loss in 1Q 2023)

Vyne Therapeutics Announces FDA Clearance of IND Application for Vyn202, A Novel Bd2-Selective Bet Inhibitor

Here's Why We're Watching VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Situation

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Announces Positive Biomarker Data from Successful Phase 1B Trial of VYN201 for the Treatment of Vitiligo

Consensus EPS estimates upgraded to US$4.82 loss, revenue downgraded

Lead Independent Director recently bought US$51k worth of stock

New major risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

VYNE Therapeutics Inc. announced that it has received $88.151509 million in funding from Acorn Bioventures, Parkman Healthcare Partners LLC, Soleus Capital, Surveyor Capital Management, Palo Alto Investors LP and other investors

VYNE Therapeutics Inc., Annual General Meeting, Dec 13, 2023

New major risk - Share price stability

Price target increased by 21% to US$16.50

New major risk - Market cap size

Consensus revenue estimates increase by 60%, EPS downgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Financial position

First quarter 2023 earnings released: US$1.72 loss per share (vs US$2.83 loss in 1Q 2022)

We're Keeping An Eye On VYNE Therapeutics' (NASDAQ:VYNE) Cash Burn Rate

Full year 2022 earnings released

VYNE Therapeutics Announces Positive Results from Phase 1a Single and Multiple Ascending Dose Trial for Investigational Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. Announces First Vitiligo Patient Dosed in Phase 1a/b Clinical Trial of Novel BET Inhibitor VYN201

VYNE Therapeutics Inc. announced that it has received $0.3 million in funding

VYNE Therapeutics Inc. Announces First Subjects Dosed in Phase 1a/b Clinical Trial Evaluating Pan-BET Inhibitor, VYN201, for the Treatment of Vitiligo

Consensus revenue estimates increase by 106%

Price target decreased to US$3.50

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

VYNE Therapeutics Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus forecasts updated

Price target decreased to US$4.00

VYNE Therapeutics Non-GAAP EPS of -$0.13 beats by $0.02, revenue of $0.13M beats by $0.03M

VYNE Therapeutics Inc. Announces Results from Its Phase 2a Trial of FMX114 for the Treatment of Mild-To-Moderate Atopic Dermatitis

Companies Like VYNE Therapeutics (NASDAQ:VYNE) Could Be Quite Risky

VYNE Therapeutics Inc. Completes Enrollment in Phase 2A Trial of FMX 114 for the Treatment of Mild-To-Moderate Atopic Dermatitis

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to US$5.80

High number of new and inexperienced directors

VYNE Therapeutics Inc. Announces Positive Phase 1b Efficacy Data for FMX114 from Phase 1b/2a Trial for the Treatment of Mild-to-Moderate Atopic Dermatitis

VYNE Therapeutics Inc. Reports Positive Preclinical Data for Intra-Articular Injection of Pan-BET Inhibitor, VYN201, in an in Vivo Model of Rheumatoid Arthritis

Consensus forecasts updated

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

VYNE Therapeutics Inc. Reports Positive Preclinical Data for Lead Bet Inhibitor, VYN201, in Human Skin Model of Vitiligo

VYNE Therapeutics Inc. Announces Phase 1B Data for Fmx114 from Phase 1B/2A Trial for the Treatment of Mild-To-Moderate Atopic Dermatitis

VYNE Therapeutics: Lots Of Clinical Risk Ahead And A Questionable Business Plan

Price target increased to US$5.80

VYNE Therapeutics (NASDAQ:VYNE) Will Have To Spend Its Cash Wisely

Third quarter 2021 earnings released: US$0.41 loss per share (vs US$0.59 loss in 3Q 2020)

Consensus forecasts updated

Second quarter 2021 earnings released: US$0.39 loss per share (vs US$4.83 loss in 2Q 2020)

Newsflash: VYNE Therapeutics Inc. (NASDAQ:VYNE) Analysts Have Been Trimming Their Revenue Forecasts

VYNE Therapeutics Inc. Announces Approval of Amzeeq (Minocycline) and Zilxi (Minocycline) in Chinese Economic Pilot Zone

VYNE Therapeutics Announces Initiation of Investigator Initiated Trial Evaluating AMZEEQ (Minocycline) with Oral Isotretinoin in Patients with Moderate to Severe Acne